We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

By LabMedica International staff writers
Posted on 04 Oct 2015
Print article
The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company.

Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI) at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) have agreed to accelerate the discovery of fully human antibodies directed against therapeutic targets being studied by investigators at Mount Sinai.

Regeneron will provide Mount Sinai with access to its proprietary VelocImmune technology and will provide financial support to use this antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease.

Fully-human monoclonal antibodies are highly desirable as therapeutic agents, for in addition to the advantages of being very specific for and tightly binding to their therapeutic targets, fully-human antibodies avoid potential immune responses that may occur in patients receiving antibodies that contain nonhuman (typically mouse) components.

The Regeneron VelocImmune mouse uniquely expresses human antibody genes in the same robust fashion that mouse genes are typically expressed. Previously engineered human monoclonal antibody-producing mice were generated with old technologies that resulted in removal of the mouse constant regions that are critical for the mouse to make a strong immune response. In contrast, VelocImmune mice preserve the mouse constant regions and, therefore, have immune systems that mount a robust, humoral-immune response that is indistinguishable from that of a normal, wild-type mouse.

Mount Sinai has agreed to undertake preclinical research operations, and Regeneron has been granted an exclusive option to negotiate a license for future clinical development and commercialization of any antibody that is developed.

"It is through partnerships like this that Mount Sinai remains on the forefront of translational research and therapeutic discoveries, and we hope to soon see the fruits of our collaboration with Regeneron," said Dr. Dennis S. Charney, dean of the Icahn School of Medicine at Mount Sinai.

"This agreement brings together Mount Sinai's deep biology and clinical expertise and Regeneron's unique antibody technology," said Dr. Drew Murphy, senior vice president for research at Regeneron. "Both our organizations are part of the rapidly maturing New York bioscience ecosystem and share a deep commitment to improving human health by pursuing innovative science."

Related Links:

Regeneron Pharmaceuticals, Inc. 
Icahn School of Medicine at Mount Sinai


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.